Rencsok, Emily M.
Slopen, Natalie
Autio, Karen
Morgans, Alicia
McSwain, Lawrence
Barata, Pedro
Cheng, Heather H.
Dreicer, Robert
Heath, Elisabeth
McKay, Rana R.
Pomerantz, Mark
Rathkopf, Dana
Tagawa, Scott
Whang, Young E.
Ragin, Camille
Odedina, Folakemi T.
George, Daniel J.
Kantoff, Philip W.
Vinson, Jacob
Villanti, Paul
Haneuse, Sebastien
Mucci, Lorelei A.
,
Funding for this research was provided by:
National Cancer Institute (F30CA264965)
National Institute of General Medical Sciences (T32GM007753, T32GM144273)
Prostate Cancer Foundation (Young Investigator, Challenge Award)
Article History
Accepted: 20 June 2023
First Online: 6 July 2023
Declarations
:
: AM consults for Astellas, AstraZeneca, AAA, Bayer, Dendreon, Exelixis, Janssen, Pfizer, Myovant, Novartis, Myriad Genetics, Lantheus, Telix, Sanofi and receives research funding from Astellas, Bayer, Pfizer, Myovant, Sanofi, SeaGen. PB consults for Astellas, AVEO Oncology, Bayer, BMS, Dendreon, Eisai, Exelixis, Janssen, EMD Serono, Guardant Health, Pfizer, Seattle Genetics; receives research support from AstraZeneca, AVEO Oncology, BlueEarth Diagnostics, Merck, Natera, Caris Life Sciences; and is part of the speaker’s bureau for Bayer, Caris Life Sciences, Pfizer, Myovant, Natera. HHC receives institutional research support from Astellas, Clovis Oncology, Color Genomics, Janssen, Medivation, Promontory Therapeutics, Sanofi; consults for AstraZeneca; and receives royalties from UpToDate. RD consults for Astellas, Aveo, Bayer, Exelixis, Gilead, Hinova, Janssen, Merck, Pfizer, Sanofi Genzyme, Tavanta. EH consults for Astellas Pharma, Bayer, Janssen Research & Development LLC, Sanofi; receives paid travel from Astellas Pharma, Caris Life Sciences, Sanofi, Seattle Genetics; receives research funding from Astellas Pharma, Arvinas, AstraZeneca, BioXcel Therapeutics, Bristol-Myers Squibb, Calibr, Calithera Biosciences Inc, Caris Life Sciences, Corcept Therapeutics, Corvis Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis, Five Prime Therapeutics, Fortis Therapeutics, GlaxoSmithKline, Gilead Sciences Inc, Harpoon Therapeutics, Hoffman-La Roche, Infinity Pharmaceuticals, iTeos Therapeutics, Janssen Research & Development LLC, Merck Sharp & Dohme Merck, Mirati Therapeutics, Modra Pharmaceuticals, Oncolys BioPharma, Peloton Therapeutics Inc, Pfizer, Pharmacyclics LLC, POINT Biopharma, Seattle Genetics; and receives honoraria from Bayer, Sanofi, and Seattle Genetics. RRM consults for Aveo, AstraZeneca, Bayer, BMS, Calithera, Caris, Dendreon, Exelixis, JNJ, Lilly, Myovant, Merck, Novartis, Pfizer, Sanofi, Sorrento Therapeutics, Telix, Tempus; receives research funding from Bayer, Tempus, AstraZeneca, Oncternal Therapeutics. DR receives institutional research support from Janssen, Bayer, AstraZeneca, Genentech, BMS/Celgene, Taiho, Promontory; serves on the board for Janssen, AstraZeneca, Bayer, Myovant, Genentech, Promontory, BMS/Celgene. ST receives institutional research support from Sanofi, Medivation, Astellas, Janssen, Amgen, Progenics, Dendreon, Lilly, Genentech, Newlink, BMS, Inovio, AstraZeneca, Immunomedics, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, Abbvie, Karyopharm, Endocyte, Clovis, Seattle Genetics, Novartis, Gilead, POINT Biopharma, Ambrx; consults for Sanofi, Medivation/Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis, Clarity, Genomic Health, POINT Biopharma, Blue Earth, AIkido Pharma, Telix Pharma, Convergent Therapeutics, EMD Serono, Myovant, Merck, Atlab Pharma, Phosplatin Therapeutics, Amgen, Ambrx; has a patent on biomarkers for sacituzumab govitecan therapy (Immunomedics / Gilead / Weill Cornell). YW receives institutional research support from Arvinas, Clovis Oncology; consults for Janssen. PWK has investment interest in Convergent Therapeutics, Context Therapeutics LLC, ESSA Pharma; serves on the board for Convergent Therapeutics, Context Therapeutics, ESSA Pharma; consults for ImmunisAI, PrognomIQ. LAM serves on the board of Convergent Therapeutics; consults for Bayer; receives institutional research support from Janssen, AstraZeneca. All other authors report no conflicts of interest.
: The original project underwent ethics review and was approved by the Institutional Review Board of the Harvard T. H. Chan School of Public Health. Informed consent was obtained from all participants in the IRONMAN Registry and included consent to access their personal demographic and health information in addition to use of their de-identified data for analyses using IRONMAN Registry data. The authors received access to de-identified IRONMAN registry data for the analyses presented here through an arrangement between the Harvard T. H. Chan School of Public Health and the Prostate Cancer Clinical Trials Consortium (the Clinical and Data Coordination Center for the IRONMAN Registry).